BioXcel Therapeutics, Inc.
BTAIQ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720893
No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.
13F holders, Q4 2021
Institutional positions in BioXcel Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 93
- −10 vs. Q3 2021
- Shares held
- 13.9M
- +1.14M (+8.9%) vs. Q3 2021
- Total value
- $283.1M
- −$105.2M (−27.1%) vs. Q3 2021
- New holders
- 15
- 38 more added
- Sold out
- 25
- 23 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BTAIQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 47 | $8.69M |
| Q1 2026 | 40 | $7.28M |
| Q4 2025 | 41 | $5.66M |
| Q3 2025 | 35 | $6.05M |
| Q2 2025 | 35 | $1.09M |
| Q1 2025 | 31 | $769.7K |
| Q4 2024 | 49 | $3.22M |
| Q3 2024 | 50 | $1.89M |
| Q2 2024 | 74 | $12.5M |
| Q1 2024 | 74 | $26.1M |
| Q4 2023 | 73 | $27.6M |
| Q3 2023 | 86 | $25.8M |
| Q2 2023 | 88 | $117.8M |
| Q1 2023 | 97 | $325.0M |
| Q4 2022 | 84 | $288.9M |
| Q3 2022 | 85 | $140.3M |
| Q2 2022 | 94 | $167.4M |
| Q1 2022 | 96 | $273.9M |
| Q4 2021 | 93 | $283.1M |
| Q3 2021 | 104 | $388.3M |
| Q2 2021 | 109 | $378.6M |
| Q1 2021 | 118 | $475.2M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding BioXcel Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −12,446−100.0% | Sold out |
| Parametric Portfolio Associates LLC | 0 | $0 | 0.00% | −11,525−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −10,076−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −9,646−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −9,438−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −8,127−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −7,967−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −7,407−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −7,350−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −6,822−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −3,589−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Glen Eagle Advisors, LLC | 0 | $0 | 0.00% | −330−100.0% | Sold out |
| Washington Trust Co | 0 | $0 | 0.00% | −250−100.0% | Sold out |
| Jacobi Capital Management LLC | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Total Clarity Wealth Management, Inc. | 0 | $0 | 0.00% | −125−100.0% | Sold out |
| Anchor Investment Management, LLC | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |